Merck paid an undisclosed sum to Elsevier to produce several volumes of a publication that had the look of a peer-reviewed medical journal, but contained only reprinted or summarized articles–most of which presented data favorable to Merck products–that appeared to act solely as marketing tools with no disclosure of company sponsorship.
This “journal”, Australasian Journal of Bone and Joint Medicine, included nine favorable “articles” about Vioxx in the second issue. For those following along at home, this was shortly before Merck yanked Vioxx on account of it killing people. Way to go, Elsevier. Nice, nice job.